Atara Biotherapeutics Stock News

Atara has been stagnant because of more than a year's worth of delay caused by the CMC review division at the FDA. I see no immediate end to the process; however, this has nearly nothing to do with th

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have been given an average recommendation of Buy by the seven analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have []

Invesco Ltd. grew its holdings in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) by 32.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 47,917 shares of the biotechnology companys stock after purchasing an additional 11,758 shares during the quarter. Invesco Ltd. owned about 0.06% of Atara Biotherapeutics []

Wall Street analysts predict that Atara Biotherapeutics, Inc. (NASDAQ:ATRA) will announce $32.47 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Atara Biotherapeutics earnings. The highest sales estimate is $50.60 million and the lowest is $3.87 million. The firm is expected to announce its next earnings []

Equities research analysts expect that Atara Biotherapeutics, Inc. (NASDAQ:ATRA) will report sales of $32.47 million for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Atara Biotherapeutics earnings. The highest sales estimate is $50.60 million and the lowest is $3.87 million. The firm is expected to announce its next earnings report []

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Jakob Dupont sold 2,199 shares of the companys stock in a transaction on Tuesday, November 16th. The stock was sold at an average price of $17.12, for a total value of $37,646.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed []

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Pascal Touchon sold 8,402 shares of the stock in a transaction on Tuesday, November 16th. The shares were sold at an average price of $17.12, for a total transaction of $143,842.24. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. []

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Pascal Touchon sold 8,402 shares of Atara Biotherapeutics stock in a transaction dated Tuesday, November 16th. The shares were sold at an average price of $17.12, for a total transaction of $143,842.24. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Shares []

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) SVP Amar Murugan sold 2,124 shares of the stock in a transaction dated Tuesday, November 16th. The shares were sold at an average price of $17.12, for a total value of $36,362.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this []

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CFO Utpal Koppikar sold 3,655 shares of the businesss stock in a transaction that occurred on Tuesday, November 16th. The stock was sold at an average price of $17.12, for a total transaction of $62,573.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC []

In the last trading session, 1.01 million Atara Biotherapeutics Inc. (NASDAQ:ATRA) shares changed hands as the companys beta touched 1.93. With the companys per share price at $17.37 changed hands at $0.3 or 1.76% during last session, the market valuation stood at $1.53B. ATRAs last price was a discount, traded about -62.35% off its 52-week Atara Biotherapeutics Inc. (NASDAQ: ATRA) Is Expected To Soar To Higher Prices In The Months To Come. Read More »

Related Stocks: TGTX , ISEE , RNW , ATRA , IMRA , MCRB , ORGN , CNP , EXTR , CSIQ ,